Isolator Integration In Cell And Gene Therapy Manufacturing

The rapid commercial expansion of cell and gene therapies has raised facility design to a critical position for consideration. CGTs are vastly different from other therapy development processes, working with and focusing on living cells rather than molecules and drug formulations. There is even extreme variety from one CGT to another. Each has different needs and requires different handling, not a one-size-fits-all approach.

Determining which processes are best suited in an isolator versus a biological safety cabinet requires an extensive, multi-perspective assessment. This white paper posits six dimensions for this evaluation, with emphasis that none are meant to be more important than another. Each is meant to provide unique information for a holistic view, better informing critical decisions. Explore this multi-dimensional evaluation model and consider what your facility might be missing in the full document below.